The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Gromova M.A.

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia

A rationally grounded approach to treating gout with regard to its onset and course and the presence of comorbidity according to the European League against Rheumatism (EULAR 2016) recommendations

Authors:

Gromova M.A.

More about the authors

Journal: Therapeutic Archive. 2017;89(12): 233‑237

DOI: 10.17116/terarkh20178912233-237

Views: 1569

Downloaded: 393

Download PDF (RU)
Contact the author
Table of contents

A RATIONALLY GROUNDED APPROACH TO TREATING GOUT WITH REGARD TO ITS ONSET AND COURSE AND THE PRESENCE OF COMORBIDITY ACCORDING TO THE EUROPEAN LEAGUE AGAINST RHEUMATISM (EULAR 2016) RECOMMENDATIONS
A RATIONALLY GROUNDED APPROACH TO TREATING GOUT WITH REGARD TO ITS ONSET AND COURSE AND THE PRESENCE OF COMORBIDITY ACCORDING TO THE EUROPEAN LEAGUE AGAINST RHEUMATISM (EULAR 2016) RECOMMENDATIONS

To cite this article:

Gromova MA. A rationally grounded approach to treating gout with regard to its onset and course and the presence of comorbidity according to the European League against Rheumatism (EULAR 2016) recommendations. Therapeutic Archive. 2017;89(12):233‑237. (In Russ.)
https://doi.org/10.17116/terarkh20178912233-237

МСФ на ЯМ
Close metadata
Recommended articles:
Traumatic damage to the diaphragm in children. Piro­gov Russian Journal of Surgery. 2024;(4):64-68
Promising approaches to the pathogenetic therapy of amyotrophic late­ral scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):13-21
Long-term follow-up of adult patients with serial and status course of epileptic seizures. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):63-68
Effi­cacy and safety of choline alfo­scerate in the preventive therapy of deme­ntia in elde­rly patients with Mild Cognitive Impairment: a three-year prospective comparative study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):92-99
Use of systemic steroids in hospitalized patients with COVID-19. Russian Journal of Preventive Medi­cine. 2024;(5):75-80
Our expe­rience in the treatment of congenital nasal median hete­rotopias in children and an overview of various treatment tactics. Russian Bulletin of Otorhinolaryngology. 2024;(2):28-32
Clinical and anatomical rationale for the effe­ctiveness of treatment of phle­gmon of the floor of the oral cavity and deep cellular spaces of the neck complicated with sepsis. Russian Journal of Operative Surgery and Clinical Anatomy. 2024;(2):19-25
B vita­mins and diseases of the peri­pheral nervous system. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):75-82
Asthenia in young patients and possibilities for its correction. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):133-137
Expe­rience with the use of risdiplam in a fami­lial case of spinal muscular atro­phy 5q in patients with a homo­zygous dele­tion of the SMN1 gene and the same copy number of the SMN2 gene. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):138-141

The review analyzes in detail the management of gout, which takes into account its onset and course and the presence of comorbidity. Emphasis is placed on drug and non-drug treatments and urate-lowering therapy in patients with kidney dysfunction. Along with allopurinol, the urate-lowering drug febuxostat is first recommended in Russia. The purpose of this review is to notify physicians of the possibility of achieving the target uric acid levels when treating gout with hyperuricemia.

Keywords:

gout
hyperuricemia
treatment
febuxostat

Authors:

Gromova M.A.

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia

List of references:

  1. Hootman JM, Helmick CG. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum. 2006;54(1):226-229.
  2. Nasonova VA, Barskova VG. Early diagnosis and treatment of gout — science based requirement for improving the employment and life prognosis of the patients. Nauchno-praktichcheskaya revmatologiya. 2004;1:5-7. (In Russ.)
  3. Luk AJ, Simkin PA. Epidemiology of hyperuricemia and gout. Am J Manag Care. 2005;11(15,Suppl):S435-442.
  4. Choi JW, Ford ES, Gao X., Choi HK. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2008;59(1):109-116.
  5. Geiderman JM. An elderly woman with a warm, painful finger. West J Med. 2000;172(1):51-52.
  6. Atakhanova LE, Tsurko VV, Buleeva IM Boiko IN, Zheleznov SP, Ivanova TB. Gout: from etiology and pathogenesis to diagnosis and rational therapy. Sovremennaya revmatologiya. 2007;1:13-18. (In Russ.)
  7. Simkin PA, Campbell PM, Larson EB. Gout in Heberden’s nodes. Arthritis Rheum. 1983;26(1):94-107.
  8. Vorobiev PA, Tsurko VV, Eliseeva ME. Gout in geriatric practice (Guidelines. Part 1). Klinicheskaya gerontologiya 2016;3-4(22):3-9. (In Russ.)
  9. Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England. JAMA. 2014;312(24):2684-2686. https://doi.org/10.1001/jama.2014.14484
  10. Rees F., Jenkins W., Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013;72(6):826-830. https://doi.org/10.1136/annrheumdis-2012-201676
  11. Dalbeth N, Chen P, White M, Gamble GD, Barratt-Boyes C, Gow PJ, Orr-Walker B. Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: a prospective longitudinal study. Ann Rheum Dis. 2014;73(5):797-802. https://doi.org/10.1136/annrheumdis-2013-203970
  12. Tsurko V.V., Eliseeva M.E., Vorobyev P.A. The specific features of gout in the elderly. Terapevticheskii Arkhiv. 2014;5(86):50-55. (In Russ.)
  13. Chen JH, Wen CP, Wu SB, Lan JL, Tsai MK, Tai YP, Lee JH, Hsu CC, Tsao CK, Wai JP, Chiang PH, Pan WH, Hsiung CA. Attenuating the mortality risk of high serum uric acid: the role of physical activity underused. Ann Rheum Dis. 2015;74(11):2034-2042. https://doi.org/10.1136/annrheumdis-2014-205312
  14. Roddy E, Choi HK. Epidemiology of gout. Rheum Dis Clin North Am. 2014;40(2):155-175. https://doi.org/10.1016/j.rdc.2014.01.001
  15. Zhang Y, Neogi T, Chen C, Chaisson C, Hunter DJ, Choi HK. Cherry consumption and decreased risk of recurrent gout attacks. Arthritis Rheum. 2012;64:4004-4011. https://doi.org/10.1002/art.34677
  16. Dalbeth N, Ames R, Gamble GD, Horne A, Wong S, Kuhn-Sherlock B, MacGibbon A, McQueen FM, Reid IR, Palmano K. Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial. Ann Rheum Dis. 2012;71(6):929-934. https://doi.org/10.1136/annrheumdis-2011-200156
  17. Liu SC, Xia L, Zhang J, Lu XH, Hu DK, Zhang HT, Li HJ. Gout and risk of myocardial infarction: a systematic review and meta-analysis of cohort studies. PLoS One. 2015;10(7):e0134088. https://doi.org/10.1371/journal.pone.0134088
  18. Clarson LE, Hider SL, Belcher J, Heneghan C, Roddy E, Mallen CD. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Ann Rheum Dis. 2015;74(4):642-647. https://doi.org/10.1136/annrheumdis-2014-205252
  19. Choi H.K., Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116(8):894-900.
  20. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060-1068. https://doi.org/10.1002/art.27327
  21. van Durme CM, Wechalekar MD, Buchbinder R, Schlesinger N, van der Heijde D, Landewé RB. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev. 2014;(9): CD010120. https://doi.org/10.1002/14651858
  22. Rainer TH, Cheng CH, Janssens HJ, Man CY, Tam LS, Choi YF, Yau WH, Lee KH, Graham CA. Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, randomized trial. Ann Intern Med. 2016;164(7):464-4671. https://doi.org/10.7326/M14-2070
  23. Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis MW. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011;63:2226-2237. https://doi.org/10.1002/art.30389
  24. Wason S., Mount D., Faulkner R. Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease. Clin Drug Investig. 2014;34(12):845-855. https://doi.org/10.1007/s40261-014-0238-6
  25. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomized equivalence trial. Lancet. 2008;371(9627):1854-1860. https://doi.org/10.1016/S0140-6736(08)60799-0
  26. Wechalekar MD, Vinik O, Schlesinger N, Buchbinder R. Intra-articular glucocorticoids for acute gout. Cochrane Database Syst Rev. 2013;(4): CD009920. https://doi.org/10.1002/14651858.CD009920
  27. Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, Krammer G, Murphy V, Richard D, So AK. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71(11):1839-1848. https://doi.org/10.1136/annrheumdis-2011-200908
  28. Ghosh P, Cho M, Rawat G, Simkin PA, Gardner GC. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care Res (Hoboken). 2013;65(8):1381-1384. https://doi.org/10.1002/acr.21989
  29. Becker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008;27(6):585-591. https://doi.org/10.1080/15257770802136032
  30. Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. ClinTher. 2010;32(14):2386-2397. https://doi.org/10.1016/j.clinthera.2011.01.008
  31. Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, Pollak U, Koren G, Bentur Y. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila). 2010;48(5):407-414. https://doi.org/10.3109/15563650.2010.495348
  32. Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540-1548. https://doi.org/10.1002/art.24209
  33. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450-2461.
  34. Clarson LE, Hider SL, Belcher J, Heneghan C, Roddy E, Mallen CD. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Ann Rheum Dis. 2015;74(4):642-647. https://doi.org/10.1136/annrheumdis-2014-205252
  35. Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010;375(9732):2161-2167. https://doi.org/10.1016/S0140-6736(10)60391-1
  36. Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O’Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study. Circulation. 2015;131(20):1763-1771. https://doi.org/10.1016/S0140-6736(10)60391-1
  37. Rothenbacher D, Primatesta P, Ferreira A, Cea-Soriano L, Rodríguez LA. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxford). 2011;50(5):973-981. https://doi.org/10.1093/rheumatology/keq363
  38. Yamanaka H. Gout and hyperuricemia in young people. Curr Opin Rheumatol. 2011;23(2): 156-60. https://doi.org/10.1097/BOR.0b013e3283432d35
  39. Bardin T. Hyperuricemia starts at 360 micromoles (6 mg/dL). Joint Bone Spine. 2015;82(3):141-143. https://doi.org/10.1016/j.jbspin.2015.01.002
  40. Weisskopf MG, O’Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson’s disease. Am J Epidemiol. 2007; 166(5): 561-567.
  41. Kim TS, Pae CU, Yoon SJ, Jang WY, Lee NJ, Kim JJ, Lee SJ, Lee C, Paik IH, Lee CU. Decreased plasma antioxidants in patients with Alzheimer’s disease. Int J Geriatric Psychiatry. 2006;21(4):344-348.
  42. Abraham A., Drory V.E. Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis. J Neurol. 2014; 261(6):1133-1138. https://doi.org/10.1007/s00415-014-7331-x
  43. Rees F., Jenkins W., Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013;72(6):826-830. https://doi.org/10.1136/annrheumdis-2012-201676
  44. Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, Naldi L, Dunant A, Viboud C, Roujeau JC. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58(1):25-32.
  45. Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540-1548. https://doi.org/10.1002/art.24209
  46. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450-2461.
  47. Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. ArthritisResTher. 2010;12(2):R63. https://doi.org/10.1186/ar2978
  48. Hira D, Chisaki Y, Noda S, Araki H, Uzu T, Maegawa H, Yano Y, Morita SY, Terada T. Population pharmacokinetics and therapeutic efficacy of febuxostat in patients with severe renal impairment. Pharmacology. 2015;96(1-2):90-98. https://doi.org/10.1159/000434633
  49. Abeles AM. Febuxostat hypersensitivity. J Rheumatol. 2012;39(3): 659. https://doi.org/10.3899/jrheum.111161
  50. Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol. 2011;38(9):1957-1959. https://doi.org/10.3899/jrheum.110092
  51. Bardin T, Chalès G, Pascart T, Flipo RM, Korng Ea H, Roujeau JC, Delayen A, Clerson P. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. Joint Bone Spine. 2016;83(3):314-317. https://doi.org/10.1016/j.jbspin.2015.07.011
  52. Kydd AS, Seth R, Buchbinder R, Edwards CJ, Bombardier C. Uricosuric medications for chronic gout. Cochrane Database Syst Rev. 2014;(11): CD010457. https://doi.org/10.1002/14651858.CD010457
  53. Choi HK, Soriano LC, Zhang Y, Rodríguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012;344:d8190. https://doi.org/10.1136/bmj.d8190
  54. Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations arereduced by fenofibrate: a systematic review and meta-analysis of randomized placebocontrolled trials. Pharmacol Res. 2015;102:63-70. https://doi.org/10.1016/j.phrs.2015.09.012
  55. Takagi H, Umemoto T. Atorvastatin therapy reduces serum uric acid levels: a meta-analysis of randomized controlled trials. Int J Cardiol. 2012;157(2):255-257. https://doi.org/10.1016/j.ijcard.2012.01.092

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.